2022 ABAI Continuous Assessment Program Literature Review - January-June
This literature review course, originally presented as part of the 2022 AAAAI Annual Meeting, will help to prepare ABAI diplomates to participate in the Continuous Assessment Program (CAP). The course will include reviews of the journal articles selected for the January-June 2021 term of the CAP to help develop greater familiarity with the key concepts included in them.
The five presentations cover a range of critical journal articles in the following topic areas:
- Food and Drug Allergy/Hypersensitivity Reactions and Eosinophilic or Gastrointestinal Disorders
- Conditions of the Head/Neck and Lungs
- Dermatologic Conditions and Anaphylaxis
- Immune Hypersensitivity Disorders and Immunodeficiencies
- Emerging National Health Priorities
Click the Program tab to access the full list of articles, with links. Please note that all CAP articles can be accessed through the ABAI web portal.
- Allergist/Immunologists participating in continuous certification with the American Board of Allergy & Immunology
- Allied health providers working in allergy/immunology settings
- Allergy/Immunology Fellows-in-Training preparing for initial certification
- Other healthcare providers with an interest in allergy/immunology
Upon completion of this activity, participants should be able to:
- Evaluate recently published research relevant to the practice of allergy/immunology
All CAP articles are listed, below.
Articles can be accessed through the ABAI web portal.
CAP 2022 – Block 1 Article-based Reference List
• Addison AB, et al. Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction. Journal of Allergy and Clinical Immunology. 2021;147(5):1704-1719. https://doi.org/10.1016/j.jaci.2020.12.641
• Bachert C, et al. Biologics for chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology. 2020;145(3):725-739. https://doi.org/10.1016/j.jaci.2020.01.020
• Kwah JH, et al. Clinical factors associated with acute exacerbations of chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2020;145(6):1598-1605. https://doi.org/10.1016/j.jaci.2020.01.023
• Nolte H, et al. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(7):2322-2331.e5. https://doi.org/10.1016/j.jaip.2020.03.041
• Bieber T, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. New England Journal of Medicine. 2021;384(12):1101-1112. https://doi.org/10.1056/nejmoa2019380
• Guttman-Yassky E, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2020;145(3):877-884. https://doi.org/10.1016/j.jaci.2019.11.025
• Ratchataswan T, et al. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. https://doi.org/10.1016/j.jaip.2020.11.034
• Tsoi LC, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. Journal of Allergy and Clinical Immunology. 2020;145(5):1406-1415. https://doi.org/10.1016/j.jaci.2019.11.047
• Abdulqawi R, et al. A Randomized Controlled Trial to Assess the Effect of Lidocaine Administered via Throat Spray and Nebulization in Patients with Refractory Chronic Cough. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(4):1640-1647. https://doi.org/doi:10.1016/j.jaip.2020.11.037
• Cazzola M, Rogliani P, Matera MG. The latest on the role of LAMAs in asthma. Journal of Allergy and Clinical Immunology. 2020;146(6):1288-1291. https://doi.org/10.1016/j.jaci.2020.06.014
• Pavord ID, et al. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1121-1132.e7. https://doi.org/doi:10.1016/j.jaip.2020.08.039
A4 Food and Drug Allergy/Hypersensitivity Reactions
• Cox AL, Eigenmann PA, Sicherer SH. Clinical Relevance of Cross-Reactivity in Food Allergy. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(1):82-99. https://doi.org/10.1016/j.jaip.2020.09.030
• Greenhawt M. Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis. Journal of Allergy and Clinical Immunology. 2020;146(6):1302-1334. https://doi.org/10.1016/j.jaci.2020.07.031
• Mori F, et al. A Multicenter Retrospective Study on Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Children: A Report from the European Network on Drug Allergy (ENDA) Group. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(3):122-131.e1. https://doi.org/10.1016/j.jaip.2019.10.049
• Waserman S, et al. Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines. Journal of Allergy and Clinical Immunology. 2021;147(5):1561-1578. https://doi.org/10.1016/j.jaci.2021.01.034
• Carter MC, et al. Idiopathic anaphylaxis yardstick: Practical recommendations for clinical practice. Annals of Allergy, Asthma & Immunology. 2020;124(1):16-27. https://doi.org/10.1016/j.anai.2019.08.024
• González-de-Olano, D, Matito A, lvarez-Twose I. Mast cell activation syndromes and anaphylaxis: Multiple diseases part of the same spectrum. Annals of Allergy, Asthma & Immunology. 2020; 124(2):143-145.e1. https://doi.org/10.1016/j.anai.2019.11.023
• Lieberman JA, Bingemann TA, Wang J. Diagnostic Challenges in Anaphylaxis. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(4):1177-1184. https://doi.org/10.1016/j.jaip.2019.11.003
• Schuler CF, et al. Prevalence of mastocytosis and hymenoptera venom allergy in the United States. Journal of Allergy and Clinical Immunology. 2021;148(5):1316-1323. https://doi.org/10.1016/j.jaci.2021.04.013
B1 Immune Hypersensitivity Disorders
• Greinacher A, et al. Thrombotic thrombocytopenia after Chadox1 Ncov-19 vaccination. New England Journal of Medicine. 2021;384(22):2092-2101. https://doi.org/10.1056/nejmoa2104840
• Johnson DB, Jakubovic BD, Sibaud V, Sise ME. Balancing Cancer Immunotherapy Efficacy and Toxicity. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(9):2898-2906. https://doi.org/doi:10.1016/j.jaip.2020.06.028
• Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. Journal of Allergy and Clinical Immunology. 2020;146(5):925-937. https://doi.org/doi:10.1016/j.jaci.2020.08.017
• Cepika A-M, et al. Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. Journal of Allergy and Clinical Immunology. 2018;142(6):1679-1695. https://doi.org/10.1016/j.jaci.2018.10.026
• Peter H-H, et al. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. Journal of Allergy and Clinical Immunology. 2020;146(3):479-491.e5. https://doi.org/10.1016/j.jaci.2020.07.016
• Thalhammer J, et al. Initial presenting manifestations in 16,486 patients with inborn errors of immunity Include infections And Noninfectious manifestations. Journal of Allergy and Clinical Immunology. 2021;148(5):1332-1341.e5 https://doi.org/10.1016/j.jaci.2021.04.015
• Verbsky JW, et al. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. Journal of Allergy and Clinical Immunology. 2021;147(2):704-712.e17. https://doi.org/10.1016/j.jaci.2020.07.021
B3 Eosinophilic or Gastrointestinal Disorders
• Carpentier C, et al. CD3−CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(6):2426-2439.e7. https://doi.org/10.1016/j.jaip.2021.01.030 \
• Lefèvre G, et al. “Idiopathic Eosinophilic Vasculitis”: Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free Patients. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(4):1329-1340.e3. https://doi.org/doi:10.1016/j.jaip.2019.12.011
• Lyles JL, et al. Very early onset eosinophilic esophagitis is common, responds to standard therapy, and demonstrates enrichment for CAPN14 genetic variants. Journal of Allergy and Clinical Immunology. 2021;147(1):244-254.e6. https://doi.org/10.1016/j.jaci.2020.10.017
• Roufosse F, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2020;146(6):1397-1405. https://doi.org/doi:10.1016/j.jaci.2020.08.037
C1 Emerging National Health Priorities
• Bingemann TA, Laubach S. Physician well-being in allergy and immunology. Annals of Allergy, Asthma & Immunology. 2021;126(3):219-227. https://doi.org/10.1016/j.anai.2020.12.006
• Gudbjartsson DF, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine. 2020;383(18):1724-1734. https://doi.org/doi:10.1056/nejmoa2026116
• Krist AH, et al. Screening for Vitamin D Deficiency in Adults US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(14):1436-1442. https://doi:10.1001/jama.2021.3069
• Ogbogu PU, Capers Q, Apter AJ. Disparities in Asthma and Allergy Care: What Can We Do? The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(2):663-669. https://doi.org/10.1016/j.jaip.2020.10.030
• Risma KA, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. Journal of Allergy and Clinical Immunology. 2021;147(6):2075-2082.e2. https://doi.org/doi:10.1016/j.jaci.2021.04.002
Programmed by the 2021-2022 AAAAI Annual Meeting Program Committee
Committee member financial disclosures are available for review here
Yamini Virkud, MD FAAAAI
University of North Carolina, Chapel Hill, NC
Relevant relationships: None
Anju T. Peters, MD MSCI FAAAAI
Northwestern University Medical School, Chicago, IL
Relevant relationships: None
John Kelso, MD FAAAAI
Scripps Clinic, La Jolla, CA
Relevant relationships: None
Yasmin W. Khan, MD
Vanderbilt University Medical Center, Nashville, TN
Relevant relationships: None
David R. Stukus, MD FAAAAI
Nationwide Children's Hospital, Columbus, OH
Relevant relationships: None
All relevant relationships disclosed by planners and faculty have been mitigated.
AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, planners and presenters are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at firstname.lastname@example.org.
Original release date: March 22, 2022. Valid for credit through December 31, 2022.
Activity-related questions should be directed to email@example.com.
- 2.50 AttendanceAttendance credit.
- 2.50 CMECME credit.